Vimarsana
Biggest News Aggregation in the World

Page 5 - Leukemia Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Leukemia Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Leukemia Program Today - Breaking & Trending Today

Nurses inspire Ohio woman who beat cancer to become one of them: 'We need people like her' - Vimarsana News

Nurses inspire Ohio woman who beat cancer to become one of them: 'We need people like her'

Ashley Gibson, 33, of Ohio, was diagnosed with leukemia and underwent intense chemotherapy with the help of a team of nurses. Inspired by that medical care, she's becoming a nurse herself.

Risk Classification, Mutational Analysis Are Key in Informing AML Management - Vimarsana News

Risk Classification, Mutational Analysis Are Key in Informing AML Management

During an OncLive® workshop titled Key Updates in the Management of Acute Myeloid Leukemia and Their Application in Clinical Practice, moderated by Naval Daver, MD, faculty reviewed updates to the classification of acute myeloid leukemia and its effects on the treatment paradigm and provided insight on the management of adverse-risk and secondary acute myeloid leukemia.

Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML - Vimarsana News

Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML

Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia - Vimarsana News

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

12.12.2022 - - Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML- No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax - ALX Oncology ... Seite 1

Kura Oncology Presents Updated Clinical Data from KOMET-001 - Vimarsana News

Kura Oncology Presents Updated Clinical Data from KOMET-001

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥...